Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

Study Design

The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomizati
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009).../ -- Reportlinker.com announces that a new market ..., Global Markets for Assisted Reproductive Devic...742/Global-Markets-for-Assisted-Reproductive-Devic...pr&utm_campaign=prnewswire ,, Global Mark...Countries in Europe and Japan. This report include...
(Date:11/20/2009)... In response to a recent...ntly available medications designed to treat and p...ute, an independent nonprofit organization, is off...r Prevention of Prostate Cancer for free downloa...article, " Drugs to Deter Some Cancers Are Not Tak...
(Date:11/19/2009)...swire-FirstCall/ -- BioCryst Pharmaceuticals, Inc.... public offering of 5,000,000 shares of its common...eeds of $48.75 million. All of the shares are bei...elf registration statement previously filed with t...as also granted the underwriters a 30-day option t...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Tailoring Breast Cancer Treatment from Harvard Women 26apos 3Bs Health Watch 58985 1Tailoring Breast Cancer Treatment from Harvard Women 26apos 3Bs Health Watch 58985 2Lilly Confirms Date and Conference Call for Third Quarter 2009 Financial Results Announcement 58983 1132nd Anniversary Nears for American Humane Association 58981 1132nd Anniversary Nears for American Humane Association 58981 2132nd Anniversary Nears for American Humane Association 58981 3132nd Anniversary Nears for American Humane Association 58981 4132nd Anniversary Nears for American Humane Association 58981 5
...da Find Ruyan E-cigarettes Safe; ..., Oct. 28 Ruyan America, Inc., announced,today th...f its electronic,smoking alternatives, specificall...ike vapor that users find satisfies their desire f...t results confirm that the Ruyan(R),E-cigarette is...
...SA meeting in Washington, D.C., WASHINGTON, Oct. ...rated for the first time in humans that a novel to...NB-001, speeds healing of,lesions as effectively a...ty or toxicity concerns., The new data provide th...n attain equivalent efficacy rates to oral systemi...
Other Medicine Technology:Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives 2Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives 3Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections 2
(Date:11/20/2009)...de used for embalming in the funeral industry were...yeloid leukemia, according to a new study publishe...al Cancer Institute . , Previous studies have sh...gnancies and brain cancer in anatomists, pathologi... have worked with formaldehyde. , For this stu...
(Date:11/20/2009)...las, TX, the new addition to blue sky scrubs will ...the USA. , Austin, TX (PR...dependent medical scrubs brand which focuses prima...bution of hospital uniforms and surgical scrub hat...r online boutique, the Austin, TX business has gro...
(Date:11/20/2009)...n with seasonal flu , , FRIDAY, Nov. 20...rting that children with asthma are more likely to...u. , "Asthma has been identified as a significa...fluenza, present in 21 percent to 30 percent in th...w researchers from the Hospital for Sick Children ...
(Date:11/20/2009)...reased food insecurity as many face problem of hun... -- Project Bread, the state,s leading anti-hunger...annual status report on hunger in the Commonwealth... caused by high unemployment, point to 554,000 peo...od insecurity has found its way into middle class ...
(Date:11/20/2009)...0 California minority advocacy gro...he Wall/Las Memorias, Latina Breast Cancer Agency,... Real Medicine Foundation today sent a letter to B... reconsider harmful and discriminatory coverage po...ly calls for an end to the practice of step therap...
Breaking Medicine News(10 mins):Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4
...increase over Q3 ,07; gross profit remains stable;...roves - (all figures are in Canadian dollars ...RNewswire-FirstCall/ - Bioniche Life Sciences,Inc....08 fiscal year, ending March 31, 2008., "One high...
...E, N.C., May 9 MedCath Corporation,(Nasdaq: MDTH...a,presentation at the Banc of America Securities 2... Four Seasons Hotel in Las Vegas., MedCath,s seni...dCath,s website ( http://www.medcath.com ) and wil...
..., TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer... specializing in the development and,commercializa... first,quarter operational and financial results.,...i-center Phase III,trial and subsequent planned co...
...Weeks of Phase Two Operations Leads to Indictment ... Eleven people have been,indicted in the second p...ive effort against individuals and health care com...ral,District of California Thomas P. O,Brien annou...
...AM, Ala., May 8 HealthSouth,Corporation (NYSE: H...lders,to, among other things, elect directors and ...nce its last stockholder meeting in May 2007., Mo...of directors was approved by more than 87% of the ...
... May 8 NutraCea (OTC Bulletin Board:,NTRZ), a wor...research and,technology, announced today that it w... Monday, May 12 after the market closes., Managem...es. Parties interested in listening to the confere...
Other Medicine News:Health News:Bioniche Reports Fiscal 2008 Third Quarter 2Health News:Bioniche Reports Fiscal 2008 Third Quarter 3Health News:Bioniche Reports Fiscal 2008 Third Quarter 4Health News:Bioniche Reports Fiscal 2008 Third Quarter 5Health News:Bioniche Reports Fiscal 2008 Third Quarter 6Health News:Bioniche Reports Fiscal 2008 Third Quarter 7Health News:Bioniche Reports Fiscal 2008 Third Quarter 8Health News:Bioniche Reports Fiscal 2008 Third Quarter 9Health News:Bioniche Reports Fiscal 2008 Third Quarter 10Health News:Bioniche Reports Fiscal 2008 Third Quarter 11Health News:Bioniche Reports Fiscal 2008 Third Quarter 12Health News:Bioniche Reports Fiscal 2008 Third Quarter 13Health News:Bioniche Reports Fiscal 2008 Third Quarter 14Health News:Bioniche Reports Fiscal 2008 Third Quarter 15Health News:Bradmer announces 2008 first quarter operational and financial results 2Health News:Bradmer announces 2008 first quarter operational and financial results 3Health News:Bradmer announces 2008 first quarter operational and financial results 4Health News:Bradmer announces 2008 first quarter operational and financial results 5Health News:Bradmer announces 2008 first quarter operational and financial results 6Health News:Bradmer announces 2008 first quarter operational and financial results 7Health News:Bradmer announces 2008 first quarter operational and financial results 8Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 2Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 3Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 4Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 5Health News:HealthSouth Board Re-Elected at Annual Shareholder Meeting 2Health News:NutraCea to Host First Quarter 2008 Conference Call on May 12. 2
...SV- lOOOHGT instrument provides standardized glare...ion test faces for the evaluation of glare disabil... Test is precisely calibrated to simulate two on-c... 150 feet. The glare level can be adjusted to simu...
Aluminum English and Metric Ruler
Ruler S/Steel
Webster Ruler
Medicine Products: